(QTRX) Quanterix - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74766Q1013

Stock: Instruments, Assays, Reagents, Services

Total Rating 16
Risk 34
Buy Signal -1.31
Medical Devices +5.1
Life Sciences Tools & Services +9.2
Market Cap: 223m
Avg Trading Vol: 3.31M USD
ATR: 9.43%
Peers RS (IBD): 25.9
Risk 5d forecast
Volatility 74.3%
Relative Tail Risk -13.3%
Reward TTM
Sharpe Ratio -0.16
Alpha -57.45
Character TTM
Beta 1.234
Beta Downside 1.029
Drawdowns 3y
Max DD 85.07%
CAGR/Max DD -0.30

EPS (Earnings per Share)

EPS (Earnings per Share) of QTRX over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.33, "2021-09": -0.43, "2021-12": -0.55, "2022-03": -0.49, "2022-06": -0.67, "2022-09": -0.95, "2022-12": -0.5, "2023-03": -0.16, "2023-06": -0.16, "2023-09": -0.21, "2023-12": -0.33, "2024-03": -0.26, "2024-06": -0.25, "2024-09": -0.2186, "2024-12": -0.3, "2025-03": -0.53, "2025-06": -0.77, "2025-09": -0.73, "2025-12": -0.47,
EPS CAGR: 1.05%
EPS Trend: -1.3%
Last SUE: -0.26
Qual. Beats: 0

Revenue

Revenue of QTRX over the last years for every Quarter: 2021-03: 27.209, 2021-06: 25.371, 2021-09: 26.68, 2021-12: 30.287, 2022-03: 29.552, 2022-06: 23.425, 2022-09: 26.364, 2022-12: 25.611, 2023-03: 28.234, 2023-06: 30.873, 2023-09: 31.06, 2023-12: 31.197, 2024-03: 31.792, 2024-06: 34.127, 2024-09: 35.411, 2024-12: 34.106, 2025-03: 30.273, 2025-06: 24.454, 2025-09: 40.15, 2025-12: 43.855,
Rev. CAGR: 11.10%
Rev. Trend: 64.9%
Last SUE: 2.49
Qual. Beats: 2

Risks

Technicals: choppy

Description: QTRX Quanterix March 05, 2026

Quanterix Corporation (QTRX) is a life sciences company. It develops and markets digital immunoassay platforms for precision health applications. The companys business model includes the sale of instruments, assays, and related reagents, alongside contract research services.

Its product portfolio features the HD-X, SR-X, and SP-X instruments, which utilize Simoa technology for protein detection and multiplex immunoassays. The companys assays include components for enzyme-based immunoassays. Contract research services encompass sample testing and custom assay development.

Quanterix focuses on neurology, oncology, immunology, and inflammation. Its target market includes academic and governmental research institutions, as well as pharmaceutical and biotechnology companies. Sales channels involve direct field sales, support organizations, and distributors globally. The company operates within the Life Sciences Tools & Services sector, which provides essential research tools and services to the broader biotechnology and pharmaceutical industries. For more detailed financial and operational insights, consider further research on ValueRay.

Headlines to watch out for

  • Simoa platform sales drive revenue growth
  • Research services contracts boost recurring income
  • Regulatory approvals impact diagnostic product launches
  • Competition from larger diagnostic firms limits market share

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -107.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.19 > 0.02 and ΔFCF/TA -9.59 > 1.0
NWC/Revenue: 99.11% < 20% (prev 237.4%; Δ -138.3% < -1%)
CFO/TA -0.18 > 3% & CFO -77.2m > Net Income -107.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.84 > 1.5 & < 3
Outstanding Shares: last quarter (46.8m) vs 12m ago 21.35% < -2%
Gross Margin: 46.70% > 18% (prev 0.60%; Δ 4.61k% > 0.5%)
Asset Turnover: 33.62% > 50% (prev 33.31%; Δ 0.30% > 0%)
Interest Coverage Ratio: -49.96 > 6 (EBITDA TTM -97.7m / Interest Expense TTM -2.29m)

Altman Z'' -9.14

A: 0.33 (Total Current Assets 212.3m - Total Current Liabilities 74.8m) / Total Assets 418.8m
B: -1.38 (Retained Earnings -577.2m / Total Assets 418.8m)
C: -0.28 (EBIT TTM -114.6m / Avg Total Assets 412.6m)
D: -4.70 (Book Value of Equity -577.9m / Total Liabilities 123.0m)
Altman-Z'' Score: -9.14 = D

Beneish M 1.00

DSRI: 0.91 (Receivables 30.0m/32.1m, Revenue 138.7m/135.4m)
GMI: 1.28 (GM 46.70% / 59.89%)
AQI: 17.07 (AQ_t 0.40 / AQ_t-1 0.02)
SGI: 1.02 (Revenue 138.7m / 135.4m)
TATA: -0.07 (NI -107.2m - CFO -77.2m) / TA 418.8m)
Beneish M-Score: 6.63 (Cap -4..+1) = D

What is the price of QTRX shares?

As of March 14, 2026, the stock is trading at USD 5.01 with a total of 329,995 shares traded.
Over the past week, the price has changed by -6.72%, over one month by -17.77%, over three months by -36.30% and over the past year by -33.61%.

Is QTRX a buy, sell or hold?

Quanterix has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold QTRX.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the QTRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 7.3 46.3%
Analysts Target Price 7.3 46.3%

QTRX Fundamental Data Overview March 13, 2026

P/S = 1.6086
P/B = 0.7952
Revenue TTM = 138.7m USD
EBIT TTM = -114.6m USD
EBITDA TTM = -97.7m USD
Long Term Debt = 37.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.92m USD (from shortTermDebt, last quarter)
Debt = 37.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.40m USD (from netDebt column, last quarter)
Enterprise Value = 142.4m USD (223.4m + Debt 37.2m - CCE 118.2m)
Interest Coverage Ratio = -49.96 (Ebit TTM -114.6m / Interest Expense TTM -2.29m)
EV/FCF = -1.78x (Enterprise Value 142.4m / FCF TTM -79.8m)
FCF Yield = -56.06% (FCF TTM -79.8m / Enterprise Value 142.4m)
FCF Margin = -57.56% (FCF TTM -79.8m / Revenue TTM 138.7m)
Net Margin = -77.24% (Net Income TTM -107.2m / Revenue TTM 138.7m)
Gross Margin = 46.70% ((Revenue TTM 138.7m - Cost of Revenue TTM 73.9m) / Revenue TTM)
Gross Margin QoQ = 45.69% (prev 42.65%)
Tobins Q-Ratio = 0.34 (Enterprise Value 142.4m / Total Assets 418.8m)
Interest Expense / Debt = 33.27% (Interest Expense 12.4m / Debt 37.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -90.5m (EBIT -114.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 212.3m / Total Current Liabilities 74.8m)
Debt / Equity = 0.13 (Debt 37.2m / totalStockholderEquity, last quarter 295.7m)
Debt / EBITDA = -0.08 (negative EBITDA) (Net Debt 7.40m / EBITDA -97.7m)
Debt / FCF = -0.09 (negative FCF - burning cash) (Net Debt 7.40m / FCF TTM -79.8m)
Total Stockholder Equity = 304.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.97% (Net Income -107.2m / Total Assets 418.8m)
RoE = -35.16% (Net Income TTM -107.2m / Total Stockholder Equity 304.8m)
RoCE = -33.50% (EBIT -114.6m / Capital Employed (Equity 304.8m + L.T.Debt 37.2m))
RoIC = -29.70% (negative operating profit) (NOPAT -90.5m / Invested Capital 304.8m)
WACC = 12.72% (E(223.4m)/V(260.7m) * Re(10.46%) + D(37.2m)/V(260.7m) * Rd(33.27%) * (1-Tc(0.21)))
Discount Rate = 10.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.11%
[DCF] Fair Price = unknown (Cash Flow -79.8m)
EPS Correlation: -1.30 | EPS CAGR: 1.05% | SUE: -0.26 | # QB: 0
Revenue Correlation: 64.91 | Revenue CAGR: 11.10% | SUE: 2.49 | # QB: 2
EPS next Quarter (2026-06-30): EPS=-0.56 | Chg7d=-0.560 | Chg30d=-0.560 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-2.08 | Chg7d=-2.080 | Chg30d=-2.080 | Revisions Net=-1 | Growth EPS=+0.0% | Growth Revenue=+23.2%
EPS next Year (2027-12-31): EPS=-1.91 | Chg7d=-1.910 | Chg30d=-1.910 | Revisions Net=-1 | Growth EPS=+8.2% | Growth Revenue=+10.4%

Additional Sources for QTRX Stock

Fund Manager Positions: Dataroma | Stockcircle